Research ExplorerPublicationsAdoptive transfer of virus-specific and tumor-specific T cel...

Adoptive transfer of virus-specific and tumor-specific T cell immunity

Standard

Adoptive transfer of virus-specific and tumor-specific T cell immunity. / Berger, Carolina; Turtle, Cameron J; Jensen, Michael C; Riddell, Stanley R.

In: CURR OPIN IMMUNOL, Vol. 21, No. 2, 04.2009, p. 224-32.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Berger, C, Turtle, CJ, Jensen, MC & Riddell, SR 2009, 'Adoptive transfer of virus-specific and tumor-specific T cell immunity', CURR OPIN IMMUNOL, vol. 21, no. 2, pp. 224-32. https://doi.org/10.1016/j.coi.2009.02.010

APA

Berger, C., Turtle, C. J., Jensen, M. C., & Riddell, S. R. (2009). Adoptive transfer of virus-specific and tumor-specific T cell immunity. CURR OPIN IMMUNOL, 21(2), 224-32. https://doi.org/10.1016/j.coi.2009.02.010

Vancouver

Berger C, Turtle CJ, Jensen MC, Riddell SR. Adoptive transfer of virus-specific and tumor-specific T cell immunity. CURR OPIN IMMUNOL. 2009 Apr;21(2):224-32. https://doi.org/10.1016/j.coi.2009.02.010

Bibtex

@article{c6d0211db9fa41dcbef2a523053d75df,
title = "Adoptive transfer of virus-specific and tumor-specific T cell immunity",
abstract = "The adoptive transfer of T cells isolated or engineered to have specificity for diseased cells represents an ideal approach for the targeted therapy of human viral and malignant diseases. The therapeutic potential of adoptive T cell therapy for infections and cancer was demonstrated in rodent models long ago, but the task of translating this approach into an effective clinical therapy has not been easy. Carefully designed clinical trials have evaluated the transfer of antigen-specific T cells in humans, and provided insight into the barriers to efficacy and strategies to improve T cell therapy. The importance of altering the host environment to facilitate persistence and function of transferred T cells and intrinsic properties of T cells that are selected or engineered for therapy in determining their fate in vivo are key issues that have recently emerged and are informing the design of the next generation of clinical trials.",
keywords = "Adoptive Transfer/methods, Animals, Antigens, Neoplasm/immunology, Humans, Models, Immunological, Neoplasms/genetics, Receptors, Antigen, T-Cell/genetics, Recombinant Fusion Proteins/genetics, T-Lymphocytes/immunology, Virus Diseases/immunology",
author = "Carolina Berger and Turtle, {Cameron J} and Jensen, {Michael C} and Riddell, {Stanley R}",
year = "2009",
month = apr,
doi = "10.1016/j.coi.2009.02.010",
language = "English",
volume = "21",
pages = "224--32",
number = "2",

}

RIS

TY - JOUR

T1 - Adoptive transfer of virus-specific and tumor-specific T cell immunity

AU - Berger, Carolina

AU - Turtle, Cameron J

AU - Jensen, Michael C

AU - Riddell, Stanley R

PY - 2009/4

Y1 - 2009/4

N2 - The adoptive transfer of T cells isolated or engineered to have specificity for diseased cells represents an ideal approach for the targeted therapy of human viral and malignant diseases. The therapeutic potential of adoptive T cell therapy for infections and cancer was demonstrated in rodent models long ago, but the task of translating this approach into an effective clinical therapy has not been easy. Carefully designed clinical trials have evaluated the transfer of antigen-specific T cells in humans, and provided insight into the barriers to efficacy and strategies to improve T cell therapy. The importance of altering the host environment to facilitate persistence and function of transferred T cells and intrinsic properties of T cells that are selected or engineered for therapy in determining their fate in vivo are key issues that have recently emerged and are informing the design of the next generation of clinical trials.

AB - The adoptive transfer of T cells isolated or engineered to have specificity for diseased cells represents an ideal approach for the targeted therapy of human viral and malignant diseases. The therapeutic potential of adoptive T cell therapy for infections and cancer was demonstrated in rodent models long ago, but the task of translating this approach into an effective clinical therapy has not been easy. Carefully designed clinical trials have evaluated the transfer of antigen-specific T cells in humans, and provided insight into the barriers to efficacy and strategies to improve T cell therapy. The importance of altering the host environment to facilitate persistence and function of transferred T cells and intrinsic properties of T cells that are selected or engineered for therapy in determining their fate in vivo are key issues that have recently emerged and are informing the design of the next generation of clinical trials.

KW - Adoptive Transfer/methods

KW - Animals

KW - Antigens, Neoplasm/immunology

KW - Humans

KW - Models, Immunological

KW - Neoplasms/genetics

KW - Receptors, Antigen, T-Cell/genetics

KW - Recombinant Fusion Proteins/genetics

KW - T-Lymphocytes/immunology

KW - Virus Diseases/immunology

U2 - 10.1016/j.coi.2009.02.010

DO - 10.1016/j.coi.2009.02.010

M3 - SCORING: Review article

C2 - 19304470

VL - 21

SP - 224

EP - 232

IS - 2

ER -